Frits Van Rhee
Concepts (585)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 164 | 2025 | 3049 | 11.580 |
Why?
| | Antibodies, Monoclonal | 26 | 2024 | 481 | 6.090 |
Why?
| | Hematopoietic Stem Cell Transplantation | 28 | 2024 | 603 | 3.240 |
Why?
| | Antineoplastic Agents | 18 | 2024 | 1222 | 3.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 42 | 2024 | 1031 | 3.170 |
Why?
| | Humans | 219 | 2025 | 52483 | 2.230 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 11 | 2025 | 125 | 2.030 |
Why?
| | Thalidomide | 24 | 2024 | 377 | 1.960 |
Why?
| | Neoplasm Recurrence, Local | 15 | 2024 | 649 | 1.750 |
Why?
| | Immunotherapy, Adoptive | 9 | 2024 | 166 | 1.710 |
Why?
| | Killer Cells, Natural | 8 | 2024 | 116 | 1.690 |
Why?
| | Transplantation, Autologous | 26 | 2024 | 488 | 1.680 |
Why?
| | Gene Expression Profiling | 28 | 2025 | 1105 | 1.630 |
Why?
| | Interleukin-6 | 12 | 2023 | 278 | 1.610 |
Why?
| | Middle Aged | 80 | 2025 | 13028 | 1.610 |
Why?
| | Neoplasm Proteins | 13 | 2022 | 334 | 1.540 |
Why?
| | Hematologic Neoplasms | 3 | 2022 | 106 | 1.520 |
Why?
| | Prognosis | 48 | 2025 | 2099 | 1.490 |
Why?
| | Aged | 80 | 2025 | 10121 | 1.440 |
Why?
| | Antigens, Neoplasm | 6 | 2014 | 147 | 1.400 |
Why?
| | Clinical Trials as Topic | 13 | 2022 | 467 | 1.380 |
Why?
| | Stem Cell Transplantation | 10 | 2022 | 185 | 1.310 |
Why?
| | B-Cell Maturation Antigen | 9 | 2025 | 98 | 1.290 |
Why?
| | Adult | 60 | 2025 | 14161 | 1.250 |
Why?
| | Gene Expression Regulation, Neoplastic | 20 | 2022 | 857 | 1.220 |
Why?
| | Combined Modality Therapy | 19 | 2024 | 639 | 1.210 |
Why?
| | Chromosomes, Human, Pair 1 | 9 | 2023 | 96 | 1.200 |
Why?
| | Male | 90 | 2025 | 26761 | 1.200 |
Why?
| | Female | 92 | 2025 | 28171 | 1.180 |
Why?
| | Herpesvirus 8, Human | 7 | 2021 | 98 | 1.170 |
Why?
| | Antibodies, Bispecific | 6 | 2025 | 94 | 1.150 |
Why?
| | Translocation, Genetic | 10 | 2022 | 265 | 1.140 |
Why?
| | Treatment Outcome | 47 | 2024 | 5422 | 1.090 |
Why?
| | Boronic Acids | 12 | 2013 | 183 | 1.070 |
Why?
| | Pyrazines | 12 | 2013 | 190 | 1.070 |
Why?
| | Bone Marrow | 18 | 2024 | 364 | 1.020 |
Why?
| | Proteasome Inhibitors | 5 | 2024 | 104 | 1.010 |
Why?
| | Plasma Cells | 12 | 2025 | 239 | 1.010 |
Why?
| | Immunotherapy | 6 | 2024 | 244 | 0.960 |
Why?
| | Neoplasms, Second Primary | 2 | 2024 | 77 | 0.940 |
Why?
| | Disease-Free Survival | 24 | 2019 | 460 | 0.910 |
Why?
| | B-Lymphocytes | 5 | 2024 | 184 | 0.880 |
Why?
| | Dexamethasone | 14 | 2024 | 438 | 0.880 |
Why?
| | T-Lymphocytes, Cytotoxic | 4 | 2014 | 66 | 0.860 |
Why?
| | Melphalan | 9 | 2020 | 181 | 0.850 |
Why?
| | Cancer Vaccines | 3 | 2010 | 78 | 0.840 |
Why?
| | Follow-Up Studies | 26 | 2024 | 2279 | 0.820 |
Why?
| | Hyperhidrosis | 1 | 2022 | 2 | 0.800 |
Why?
| | Sweat | 1 | 2022 | 9 | 0.790 |
Why?
| | Survival Rate | 24 | 2020 | 945 | 0.770 |
Why?
| | Lymphoma, B-Cell | 3 | 2022 | 61 | 0.770 |
Why?
| | Drug Approval | 1 | 2022 | 46 | 0.760 |
Why?
| | Positron-Emission Tomography | 8 | 2025 | 301 | 0.730 |
Why?
| | Ehrlichia chaffeensis | 1 | 2021 | 4 | 0.730 |
Why?
| | Patient Participation | 1 | 2022 | 69 | 0.730 |
Why?
| | Ehrlichiosis | 1 | 2021 | 14 | 0.720 |
Why?
| | T-Lymphocytes | 8 | 2024 | 340 | 0.720 |
Why?
| | Cryosurgery | 1 | 2021 | 36 | 0.720 |
Why?
| | Immunoglobulin Light Chains | 3 | 2017 | 90 | 0.700 |
Why?
| | Disease Progression | 17 | 2025 | 871 | 0.700 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 30 | 0.690 |
Why?
| | Embolization, Therapeutic | 1 | 2021 | 88 | 0.680 |
Why?
| | Aged, 80 and over | 22 | 2025 | 3392 | 0.680 |
Why?
| | Cell Proliferation | 10 | 2023 | 1023 | 0.660 |
Why?
| | Neoplasm, Residual | 9 | 2025 | 173 | 0.650 |
Why?
| | Chromosomal Instability | 1 | 2019 | 16 | 0.640 |
Why?
| | Neoplasms, Plasma Cell | 3 | 2024 | 37 | 0.630 |
Why?
| | Membrane Proteins | 3 | 2006 | 335 | 0.630 |
Why?
| | Survival Analysis | 18 | 2024 | 673 | 0.620 |
Why?
| | Adrenal Cortex Hormones | 2 | 2023 | 116 | 0.610 |
Why?
| | Immunologic Factors | 2 | 2018 | 117 | 0.600 |
Why?
| | Epigenesis, Genetic | 4 | 2023 | 406 | 0.580 |
Why?
| | Tumor Microenvironment | 6 | 2024 | 256 | 0.580 |
Why?
| | Chromosome Aberrations | 12 | 2023 | 297 | 0.580 |
Why?
| | POEMS Syndrome | 1 | 2018 | 34 | 0.570 |
Why?
| | Dendritic Cells | 3 | 2014 | 136 | 0.570 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 200 | 0.560 |
Why?
| | Thyroid Neoplasms | 1 | 2019 | 116 | 0.560 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2024 | 505 | 0.550 |
Why?
| | Prealbumin | 2 | 2014 | 22 | 0.550 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2023 | 236 | 0.530 |
Why?
| | Receptors, Interleukin-6 | 2 | 2014 | 23 | 0.530 |
Why?
| | Cardiomyopathies | 2 | 2014 | 121 | 0.490 |
Why?
| | Mutation | 10 | 2022 | 1347 | 0.480 |
Why?
| | Risk Assessment | 11 | 2025 | 1327 | 0.470 |
Why?
| | Osteolysis | 4 | 2022 | 75 | 0.470 |
Why?
| | Immunotoxins | 1 | 2014 | 6 | 0.450 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2024 | 326 | 0.440 |
Why?
| | Recurrence | 13 | 2024 | 672 | 0.440 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2012 | 58 | 0.440 |
Why?
| | Risk Factors | 20 | 2025 | 3889 | 0.440 |
Why?
| | Clonal Evolution | 3 | 2020 | 58 | 0.430 |
Why?
| | Practice Guidelines as Topic | 4 | 2023 | 488 | 0.430 |
Why?
| | Cyclophosphamide | 5 | 2021 | 171 | 0.420 |
Why?
| | Health Status | 1 | 2015 | 294 | 0.410 |
Why?
| | Amyloidosis | 1 | 2014 | 85 | 0.410 |
Why?
| | Transplantation, Homologous | 5 | 2017 | 150 | 0.410 |
Why?
| | Thrombocytopenia | 3 | 2025 | 89 | 0.410 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2025 | 133 | 0.400 |
Why?
| | Fluorodeoxyglucose F18 | 6 | 2021 | 188 | 0.400 |
Why?
| | Remission Induction | 13 | 2021 | 218 | 0.390 |
Why?
| | Neutropenia | 2 | 2023 | 115 | 0.380 |
Why?
| | Genome-Wide Association Study | 3 | 2024 | 186 | 0.380 |
Why?
| | Receptors, KIR | 2 | 2008 | 12 | 0.380 |
Why?
| | Genetic Predisposition to Disease | 3 | 2024 | 528 | 0.360 |
Why?
| | Bone Diseases | 3 | 2021 | 96 | 0.360 |
Why?
| | Pyrimidines | 2 | 2022 | 199 | 0.360 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2020 | 1378 | 0.360 |
Why?
| | Prospective Studies | 9 | 2025 | 2481 | 0.360 |
Why?
| | Cytokines | 3 | 2025 | 623 | 0.360 |
Why?
| | Lymph Nodes | 5 | 2025 | 258 | 0.350 |
Why?
| | Azacitidine | 1 | 2010 | 39 | 0.350 |
Why?
| | Benzamides | 1 | 2010 | 50 | 0.350 |
Why?
| | Evolution, Molecular | 2 | 2021 | 93 | 0.350 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2010 | 58 | 0.340 |
Why?
| | C-Reactive Protein | 6 | 2022 | 155 | 0.330 |
Why?
| | Prednisone | 2 | 2021 | 102 | 0.330 |
Why?
| | Doxorubicin | 6 | 2021 | 241 | 0.330 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2020 | 80 | 0.320 |
Why?
| | Drug Administration Schedule | 5 | 2015 | 374 | 0.320 |
Why?
| | Chromosome Deletion | 5 | 2023 | 142 | 0.320 |
Why?
| | Metaphase | 4 | 2016 | 46 | 0.310 |
Why?
| | Pelvis | 2 | 2021 | 69 | 0.310 |
Why?
| | Quality of Life | 1 | 2015 | 879 | 0.310 |
Why?
| | Vaccination | 4 | 2022 | 298 | 0.310 |
Why?
| | Membrane Glycoproteins | 2 | 2009 | 244 | 0.300 |
Why?
| | Paraproteinemias | 3 | 2022 | 74 | 0.300 |
Why?
| | Disease Management | 3 | 2025 | 188 | 0.300 |
Why?
| | Animals | 15 | 2024 | 13505 | 0.290 |
Why?
| | Proportional Hazards Models | 7 | 2024 | 443 | 0.290 |
Why?
| | Placebo Effect | 2 | 2020 | 16 | 0.290 |
Why?
| | Fever | 3 | 2025 | 112 | 0.290 |
Why?
| | Bone Neoplasms | 4 | 2013 | 184 | 0.290 |
Why?
| | Young Adult | 8 | 2025 | 4329 | 0.290 |
Why?
| | Adoptive Transfer | 1 | 2007 | 29 | 0.290 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2007 | 48 | 0.280 |
Why?
| | Chromatin | 3 | 2023 | 139 | 0.280 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2024 | 132 | 0.280 |
Why?
| | Cytogenetic Analysis | 5 | 2023 | 80 | 0.280 |
Why?
| | Registries | 4 | 2025 | 581 | 0.270 |
Why?
| | Boron Compounds | 2 | 2024 | 19 | 0.270 |
Why?
| | DNA Methylation | 4 | 2023 | 592 | 0.270 |
Why?
| | Chromans | 2 | 2024 | 35 | 0.270 |
Why?
| | Vincristine | 3 | 2021 | 88 | 0.260 |
Why?
| | Cell Membrane | 1 | 2007 | 245 | 0.260 |
Why?
| | Mice, SCID | 6 | 2013 | 182 | 0.260 |
Why?
| | Glycine | 2 | 2024 | 75 | 0.260 |
Why?
| | Angiogenesis Inhibitors | 5 | 2010 | 183 | 0.260 |
Why?
| | Down-Regulation | 1 | 2007 | 346 | 0.260 |
Why?
| | In Situ Hybridization, Fluorescence | 5 | 2023 | 263 | 0.250 |
Why?
| | Neoplasm Staging | 6 | 2024 | 772 | 0.250 |
Why?
| | Consensus | 3 | 2025 | 181 | 0.250 |
Why?
| | Chromosomes, Human, Pair 17 | 2 | 2017 | 35 | 0.240 |
Why?
| | Cell Line, Tumor | 9 | 2023 | 1470 | 0.240 |
Why?
| | Vitamin E | 2 | 2024 | 77 | 0.240 |
Why?
| | Transplantation Conditioning | 5 | 2008 | 93 | 0.240 |
Why?
| | Case-Control Studies | 6 | 2024 | 1201 | 0.240 |
Why?
| | Bone Resorption | 2 | 2022 | 302 | 0.240 |
Why?
| | Mice | 11 | 2024 | 5949 | 0.240 |
Why?
| | Infusions, Intravenous | 3 | 2015 | 220 | 0.240 |
Why?
| | Connective Tissue Diseases | 1 | 2025 | 20 | 0.240 |
Why?
| | Antibody Formation | 1 | 2005 | 51 | 0.230 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2025 | 63 | 0.230 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2021 | 48 | 0.220 |
Why?
| | Time Factors | 11 | 2021 | 2968 | 0.220 |
Why?
| | Autoantibodies | 1 | 2025 | 121 | 0.220 |
Why?
| | Flow Cytometry | 4 | 2012 | 478 | 0.220 |
Why?
| | Monocytes | 2 | 2020 | 130 | 0.220 |
Why?
| | Gene Expression | 2 | 2018 | 618 | 0.220 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2022 | 182 | 0.210 |
Why?
| | Cell Cycle Proteins | 2 | 2022 | 169 | 0.210 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2024 | 96 | 0.210 |
Why?
| | Blotting, Western | 3 | 2015 | 590 | 0.210 |
Why?
| | Proteasome Endopeptidase Complex | 3 | 2011 | 117 | 0.210 |
Why?
| | Epstein-Barr Virus Infections | 2 | 2020 | 32 | 0.210 |
Why?
| | Signal Transduction | 6 | 2021 | 1671 | 0.210 |
Why?
| | Radiation-Protective Agents | 1 | 2024 | 72 | 0.210 |
Why?
| | Integrin beta Chains | 1 | 2023 | 14 | 0.210 |
Why?
| | Integrins | 1 | 2023 | 31 | 0.200 |
Why?
| | Retrospective Studies | 11 | 2025 | 6607 | 0.200 |
Why?
| | Double-Blind Method | 2 | 2015 | 713 | 0.200 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 1678 | 0.200 |
Why?
| | Sweating | 1 | 2022 | 13 | 0.200 |
Why?
| | Hematopoietic Stem Cells | 2 | 2022 | 187 | 0.200 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2020 | 81 | 0.190 |
Why?
| | DNA, Intergenic | 1 | 2022 | 6 | 0.190 |
Why?
| | Tumor Cells, Cultured | 4 | 2013 | 460 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 10 | 2016 | 483 | 0.190 |
Why?
| | Proteomics | 3 | 2021 | 329 | 0.190 |
Why?
| | Immunoconjugates | 1 | 2022 | 39 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2022 | 54 | 0.190 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 221 | 0.190 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2022 | 40 | 0.190 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 98 | 0.190 |
Why?
| | United States | 4 | 2022 | 5192 | 0.190 |
Why?
| | Influenza, Human | 1 | 2022 | 93 | 0.180 |
Why?
| | Mediastinum | 1 | 2021 | 21 | 0.180 |
Why?
| | Chromosomes, Human, Pair 14 | 3 | 2020 | 75 | 0.180 |
Why?
| | Epigenomics | 1 | 2021 | 75 | 0.180 |
Why?
| | Receptors, Glucocorticoid | 2 | 2012 | 34 | 0.180 |
Why?
| | Apoptosis | 5 | 2018 | 1119 | 0.180 |
Why?
| | Ubiquitination | 1 | 2021 | 47 | 0.180 |
Why?
| | Axilla | 1 | 2021 | 92 | 0.180 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2019 | 151 | 0.180 |
Why?
| | Multiple Organ Failure | 1 | 2021 | 49 | 0.180 |
Why?
| | Alleles | 3 | 2021 | 276 | 0.180 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 91 | 0.180 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 106 | 0.180 |
Why?
| | Salvage Therapy | 6 | 2013 | 136 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-maf | 2 | 2020 | 19 | 0.180 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2020 | 1 | 0.170 |
Why?
| | Rare Diseases | 1 | 2020 | 47 | 0.170 |
Why?
| | Adolescent | 7 | 2025 | 6739 | 0.170 |
Why?
| | Interferon-gamma | 3 | 2014 | 180 | 0.170 |
Why?
| | Transcriptome | 5 | 2025 | 370 | 0.170 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 74 | 0.170 |
Why?
| | Radiopharmaceuticals | 4 | 2021 | 204 | 0.170 |
Why?
| | Cell Cycle | 1 | 2021 | 230 | 0.170 |
Why?
| | Longitudinal Studies | 5 | 2024 | 747 | 0.170 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.170 |
Why?
| | Interferon Type I | 1 | 2020 | 27 | 0.170 |
Why?
| | Leukemia, Plasma Cell | 1 | 2020 | 33 | 0.170 |
Why?
| | Myelodysplastic Syndromes | 2 | 2013 | 86 | 0.170 |
Why?
| | Research Design | 2 | 2020 | 359 | 0.160 |
Why?
| | Multivariate Analysis | 8 | 2021 | 591 | 0.160 |
Why?
| | ROC Curve | 2 | 2025 | 253 | 0.160 |
Why?
| | Genomics | 4 | 2023 | 268 | 0.160 |
Why?
| | Gene Amplification | 1 | 2019 | 58 | 0.160 |
Why?
| | Measles virus | 1 | 2019 | 8 | 0.160 |
Why?
| | Measles | 1 | 2019 | 8 | 0.160 |
Why?
| | DNA | 1 | 2023 | 549 | 0.160 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.160 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 111 | 0.160 |
Why?
| | Data Collection | 1 | 2020 | 290 | 0.160 |
Why?
| | Immunohistochemistry | 2 | 2015 | 979 | 0.160 |
Why?
| | Oncolytic Virotherapy | 1 | 2019 | 21 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2022 | 215 | 0.160 |
Why?
| | Biopsy | 5 | 2018 | 605 | 0.160 |
Why?
| | Patient Safety | 1 | 2020 | 104 | 0.160 |
Why?
| | Sirolimus | 1 | 2019 | 65 | 0.150 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.150 |
Why?
| | Cell Differentiation | 6 | 2022 | 665 | 0.150 |
Why?
| | Precancerous Conditions | 2 | 2010 | 85 | 0.150 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 261 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2019 | 169 | 0.150 |
Why?
| | Syndrome | 1 | 2019 | 247 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2022 | 299 | 0.150 |
Why?
| | MafB Transcription Factor | 1 | 2018 | 9 | 0.150 |
Why?
| | Graft vs Host Disease | 4 | 2007 | 87 | 0.150 |
Why?
| | Spleen | 1 | 2019 | 172 | 0.150 |
Why?
| | Genomic Instability | 2 | 2016 | 89 | 0.150 |
Why?
| | Phosphotransferases | 1 | 2018 | 17 | 0.150 |
Why?
| | Immunomodulation | 1 | 2018 | 38 | 0.150 |
Why?
| | Chemokines | 1 | 2018 | 79 | 0.140 |
Why?
| | Plasma | 1 | 2018 | 45 | 0.140 |
Why?
| | Myeloablative Agonists | 2 | 2008 | 32 | 0.140 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2008 | 60 | 0.140 |
Why?
| | Osteoclasts | 3 | 2022 | 428 | 0.140 |
Why?
| | Genes, Neoplasm | 2 | 2015 | 31 | 0.140 |
Why?
| | Adipocytes | 1 | 2018 | 132 | 0.140 |
Why?
| | Models, Biological | 2 | 2018 | 735 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 5 | 2013 | 1546 | 0.140 |
Why?
| | Gene Dosage | 2 | 2015 | 78 | 0.140 |
Why?
| | Gene Rearrangement | 1 | 2018 | 75 | 0.140 |
Why?
| | Hexokinase | 1 | 2017 | 16 | 0.140 |
Why?
| | Communication | 1 | 2019 | 257 | 0.140 |
Why?
| | Heterozygote | 2 | 2014 | 90 | 0.140 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2018 | 87 | 0.130 |
Why?
| | HLA-A Antigens | 2 | 2007 | 11 | 0.130 |
Why?
| | Calcification, Physiologic | 1 | 2017 | 42 | 0.130 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 395 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 405 | 0.130 |
Why?
| | Gene Frequency | 2 | 2013 | 98 | 0.130 |
Why?
| | Syndecan-1 | 4 | 2021 | 74 | 0.130 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 179 | 0.120 |
Why?
| | Lymphocyte Activation | 2 | 2017 | 172 | 0.120 |
Why?
| | Critical Illness | 1 | 2018 | 317 | 0.120 |
Why?
| | Tumor Burden | 3 | 2020 | 136 | 0.120 |
Why?
| | Confidence Intervals | 2 | 2014 | 158 | 0.120 |
Why?
| | Erythrocyte Indices | 1 | 2015 | 7 | 0.120 |
Why?
| | Biomarkers, Pharmacological | 2 | 2012 | 26 | 0.120 |
Why?
| | Immunity, Innate | 1 | 2016 | 117 | 0.120 |
Why?
| | DNA Copy Number Variations | 3 | 2022 | 117 | 0.120 |
Why?
| | Coculture Techniques | 2 | 2013 | 144 | 0.120 |
Why?
| | Hemoglobins | 2 | 2013 | 112 | 0.120 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.110 |
Why?
| | Hematologic Diseases | 1 | 2014 | 21 | 0.110 |
Why?
| | Half-Life | 1 | 2014 | 88 | 0.110 |
Why?
| | International Cooperation | 1 | 2014 | 49 | 0.110 |
Why?
| | Fatigue | 1 | 2015 | 125 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 235 | 0.110 |
Why?
| | Iron | 1 | 2015 | 127 | 0.110 |
Why?
| | Area Under Curve | 1 | 2014 | 180 | 0.110 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2013 | 5 | 0.110 |
Why?
| | Antibodies | 2 | 2024 | 159 | 0.110 |
Why?
| | Reference Values | 1 | 2014 | 313 | 0.110 |
Why?
| | Antineoplastic Agents, Alkylating | 3 | 2008 | 77 | 0.110 |
Why?
| | Emotions | 1 | 2015 | 174 | 0.110 |
Why?
| | Renal Insufficiency | 2 | 2021 | 113 | 0.110 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2014 | 41 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2014 | 1026 | 0.110 |
Why?
| | Disease Models, Animal | 2 | 2016 | 1478 | 0.110 |
Why?
| | Administration, Metronomic | 1 | 2013 | 7 | 0.110 |
Why?
| | Inflammation Mediators | 1 | 2014 | 115 | 0.110 |
Why?
| | Cystatin M | 2 | 2024 | 19 | 0.110 |
Why?
| | Cisplatin | 4 | 2013 | 285 | 0.100 |
Why?
| | Macaca mulatta | 2 | 2024 | 92 | 0.100 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 6 | 0.100 |
Why?
| | Central Nervous System Neoplasms | 1 | 2013 | 68 | 0.100 |
Why?
| | beta Catenin | 1 | 2013 | 102 | 0.100 |
Why?
| | Oligopeptides | 1 | 2013 | 92 | 0.100 |
Why?
| | Venous Thrombosis | 2 | 2004 | 90 | 0.100 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 2 | 2009 | 12 | 0.100 |
Why?
| | Leukemia | 1 | 2013 | 67 | 0.100 |
Why?
| | Myelolipoma | 1 | 2012 | 9 | 0.100 |
Why?
| | Edema | 2 | 2025 | 66 | 0.100 |
Why?
| | Cell Survival | 2 | 2020 | 612 | 0.100 |
Why?
| | Pain | 1 | 2015 | 362 | 0.100 |
Why?
| | Mental Health | 1 | 2015 | 240 | 0.100 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2012 | 8 | 0.100 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 9 | 0.100 |
Why?
| | Clone Cells | 2 | 2023 | 77 | 0.100 |
Why?
| | Maintenance Chemotherapy | 1 | 2012 | 51 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 182 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2024 | 202 | 0.100 |
Why?
| | Models, Genetic | 2 | 2016 | 169 | 0.100 |
Why?
| | Interleukin-2 | 1 | 2012 | 69 | 0.100 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 92 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 137 | 0.090 |
Why?
| | Cell Movement | 1 | 2013 | 268 | 0.090 |
Why?
| | Hemangioma | 1 | 2013 | 84 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 2012 | 57 | 0.090 |
Why?
| | Immunoglobulin G | 2 | 2025 | 195 | 0.090 |
Why?
| | Genotype | 1 | 2013 | 566 | 0.090 |
Why?
| | Arkansas | 5 | 2021 | 2028 | 0.090 |
Why?
| | Transcriptional Elongation Factors | 2 | 2022 | 17 | 0.090 |
Why?
| | Transduction, Genetic | 2 | 2014 | 44 | 0.090 |
Why?
| | Chemokine CXCL13 | 2 | 2022 | 6 | 0.090 |
Why?
| | Models, Statistical | 2 | 2014 | 230 | 0.090 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 2 | 2008 | 59 | 0.090 |
Why?
| | Mutation Rate | 2 | 2021 | 36 | 0.090 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2010 | 5 | 0.090 |
Why?
| | Hypersensitivity, Delayed | 1 | 2010 | 18 | 0.090 |
Why?
| | CD40 Ligand | 1 | 2010 | 15 | 0.090 |
Why?
| | Interleukin-4 | 1 | 2010 | 44 | 0.090 |
Why?
| | Secondary Prevention | 1 | 2010 | 84 | 0.090 |
Why?
| | Up-Regulation | 4 | 2018 | 454 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2010 | 28 | 0.080 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2010 | 17 | 0.080 |
Why?
| | Immunity, Cellular | 1 | 2010 | 64 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 52 | 0.080 |
Why?
| | Cell Line | 2 | 2013 | 1030 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2013 | 1567 | 0.080 |
Why?
| | Etoposide | 2 | 2007 | 74 | 0.080 |
Why?
| | Ovarian Neoplasms | 1 | 2014 | 459 | 0.080 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 79 | 0.080 |
Why?
| | Placenta | 1 | 2011 | 153 | 0.080 |
Why?
| | Radiography | 4 | 2012 | 470 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 461 | 0.080 |
Why?
| | Histones | 2 | 2021 | 314 | 0.080 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2008 | 26 | 0.080 |
Why?
| | Hospitalization | 2 | 2024 | 736 | 0.080 |
Why?
| | Transcription Factors | 2 | 2023 | 566 | 0.080 |
Why?
| | Liver Neoplasms | 1 | 2012 | 333 | 0.070 |
Why?
| | Lymphocyte Subsets | 1 | 2008 | 14 | 0.070 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2008 | 15 | 0.070 |
Why?
| | Haplotypes | 1 | 2008 | 92 | 0.070 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2008 | 64 | 0.070 |
Why?
| | Cytogenetics | 1 | 2008 | 23 | 0.070 |
Why?
| | Bone and Bones | 3 | 2021 | 494 | 0.070 |
Why?
| | Gene Deletion | 1 | 2009 | 272 | 0.070 |
Why?
| | Neoplastic Stem Cells | 1 | 2009 | 99 | 0.070 |
Why?
| | Ligands | 1 | 2008 | 206 | 0.070 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 39 | 0.070 |
Why?
| | Osteogenesis | 1 | 2011 | 366 | 0.070 |
Why?
| | Twins | 1 | 2007 | 33 | 0.070 |
Why?
| | Busulfan | 1 | 2007 | 17 | 0.070 |
Why?
| | Diphosphonates | 1 | 2008 | 92 | 0.070 |
Why?
| | Herpesviridae Infections | 2 | 2019 | 57 | 0.070 |
Why?
| | Immunophenotyping | 1 | 2007 | 117 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 1 | 2007 | 123 | 0.070 |
Why?
| | Caspases | 2 | 2018 | 104 | 0.070 |
Why?
| | Antimetabolites | 1 | 2006 | 12 | 0.070 |
Why?
| | Creatinine | 1 | 2007 | 150 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2012 | 505 | 0.070 |
Why?
| | Blood Proteins | 1 | 2007 | 85 | 0.070 |
Why?
| | Antibodies, Neoplasm | 1 | 2006 | 28 | 0.070 |
Why?
| | Graft vs Leukemia Effect | 1 | 2006 | 2 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 243 | 0.060 |
Why?
| | Chromosome Banding | 1 | 2006 | 24 | 0.060 |
Why?
| | Plasmacytoma | 1 | 2006 | 43 | 0.060 |
Why?
| | Cohort Studies | 3 | 2020 | 1542 | 0.060 |
Why?
| | Amiloride | 1 | 2005 | 7 | 0.060 |
Why?
| | HLA-A2 Antigen | 1 | 2005 | 11 | 0.060 |
Why?
| | Bone Marrow Transplantation | 2 | 2022 | 113 | 0.060 |
Why?
| | MicroRNAs | 1 | 2010 | 387 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 154 | 0.060 |
Why?
| | Decision Trees | 1 | 2025 | 22 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 891 | 0.060 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2016 | 29 | 0.060 |
Why?
| | Japan | 1 | 2025 | 38 | 0.060 |
Why?
| | Predictive Value of Tests | 3 | 2018 | 944 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 1165 | 0.060 |
Why?
| | Child | 3 | 2025 | 7248 | 0.060 |
Why?
| | Autoantigens | 1 | 2025 | 53 | 0.060 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2024 | 6 | 0.060 |
Why?
| | Mendelian Randomization Analysis | 1 | 2024 | 7 | 0.060 |
Why?
| | Phthalimides | 1 | 2024 | 3 | 0.060 |
Why?
| | Piperidones | 1 | 2024 | 7 | 0.060 |
Why?
| | Enoxaparin | 1 | 2004 | 31 | 0.060 |
Why?
| | Telomere | 1 | 2024 | 38 | 0.060 |
Why?
| | Retreatment | 1 | 2024 | 58 | 0.060 |
Why?
| | NF-kappa B | 2 | 2018 | 322 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 66 | 0.050 |
Why?
| | Ferritins | 1 | 2024 | 36 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 79 | 0.050 |
Why?
| | Cost of Illness | 1 | 2024 | 121 | 0.050 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2024 | 56 | 0.050 |
Why?
| | Epidemiologic Methods | 3 | 2008 | 46 | 0.050 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 146 | 0.050 |
Why?
| | Gene Silencing | 2 | 2016 | 118 | 0.050 |
Why?
| | Neoplasms | 1 | 2014 | 1325 | 0.050 |
Why?
| | Fibroblasts | 1 | 2005 | 355 | 0.050 |
Why?
| | Cluster Analysis | 3 | 2010 | 233 | 0.050 |
Why?
| | Cell Communication | 1 | 2023 | 71 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| | Patients | 1 | 2022 | 51 | 0.050 |
Why?
| | Geography | 1 | 2022 | 65 | 0.050 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2022 | 34 | 0.050 |
Why?
| | Whole-Body Irradiation | 1 | 2022 | 127 | 0.050 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2022 | 17 | 0.050 |
Why?
| | Phenotype | 1 | 2025 | 789 | 0.050 |
Why?
| | Inheritance Patterns | 1 | 2022 | 22 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2022 | 62 | 0.050 |
Why?
| | Patient Selection | 1 | 2023 | 259 | 0.050 |
Why?
| | Quantitative Trait Loci | 1 | 2022 | 50 | 0.050 |
Why?
| | Risk | 2 | 2014 | 316 | 0.050 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2022 | 36 | 0.050 |
Why?
| | Oncogenes | 1 | 2021 | 60 | 0.050 |
Why?
| | Phylogeny | 1 | 2022 | 231 | 0.050 |
Why?
| | Anticoagulants | 1 | 2004 | 270 | 0.050 |
Why?
| | Age of Onset | 2 | 2013 | 110 | 0.050 |
Why?
| | RANK Ligand | 1 | 2022 | 187 | 0.040 |
Why?
| | SOXC Transcription Factors | 1 | 2021 | 13 | 0.040 |
Why?
| | Rabbits | 2 | 2013 | 375 | 0.040 |
Why?
| | Child, Preschool | 2 | 2020 | 4076 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2022 | 185 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2021 | 122 | 0.040 |
Why?
| | Base Sequence | 1 | 2022 | 640 | 0.040 |
Why?
| | Cyclin D2 | 1 | 2020 | 21 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 18 | 0.040 |
Why?
| | Fibrosis | 1 | 2021 | 196 | 0.040 |
Why?
| | Spatio-Temporal Analysis | 1 | 2020 | 11 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2022 | 155 | 0.040 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.040 |
Why?
| | ras Proteins | 1 | 2020 | 64 | 0.040 |
Why?
| | Histone Code | 1 | 2020 | 32 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2020 | 57 | 0.040 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 55 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2020 | 32 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 121 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 227 | 0.040 |
Why?
| | Genetic Loci | 1 | 2020 | 49 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2021 | 552 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 81 | 0.040 |
Why?
| | False Negative Reactions | 1 | 2019 | 30 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 180 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 278 | 0.040 |
Why?
| | Genetic Variation | 1 | 2020 | 230 | 0.040 |
Why?
| | Incidence | 2 | 2013 | 1062 | 0.040 |
Why?
| | Europe | 1 | 2019 | 87 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 43 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2019 | 38 | 0.040 |
Why?
| | Computational Biology | 1 | 2020 | 212 | 0.040 |
Why?
| | beta 2-Microglobulin | 2 | 2009 | 39 | 0.040 |
Why?
| | Genome, Viral | 1 | 2019 | 83 | 0.040 |
Why?
| | DNA, Viral | 1 | 2019 | 137 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2016 | 1132 | 0.040 |
Why?
| | Virus Diseases | 1 | 2019 | 46 | 0.040 |
Why?
| | Fibrinogen | 1 | 2018 | 34 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2018 | 45 | 0.040 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2018 | 21 | 0.040 |
Why?
| | Bone Marrow Cells | 2 | 2014 | 190 | 0.040 |
Why?
| | Platelet Count | 2 | 2008 | 75 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 422 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 467 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.040 |
Why?
| | Pathology, Molecular | 1 | 2018 | 28 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 61 | 0.040 |
Why?
| | Data Interpretation, Statistical | 2 | 2010 | 164 | 0.040 |
Why?
| | Databases, Factual | 2 | 2013 | 706 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2017 | 54 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2017 | 63 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 124 | 0.030 |
Why?
| | Lamins | 1 | 2016 | 5 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 184 | 0.030 |
Why?
| | Chromosomes, Human, Pair 16 | 1 | 2016 | 18 | 0.030 |
Why?
| | Internationality | 1 | 2017 | 43 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2018 | 578 | 0.030 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 94 | 0.030 |
Why?
| | Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 78 | 0.030 |
Why?
| | Genes, p53 | 1 | 2016 | 52 | 0.030 |
Why?
| | Proteolysis | 1 | 2016 | 101 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 270 | 0.030 |
Why?
| | Glycolysis | 1 | 2016 | 73 | 0.030 |
Why?
| | Chromosome Mapping | 2 | 2006 | 154 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 1006 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 107 | 0.030 |
Why?
| | Phosphorylation | 1 | 2016 | 528 | 0.030 |
Why?
| | Kidney Diseases | 1 | 2017 | 220 | 0.030 |
Why?
| | Myocardium | 1 | 2017 | 453 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2014 | 38 | 0.030 |
Why?
| | Gene Fusion | 1 | 2014 | 9 | 0.030 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2014 | 7 | 0.030 |
Why?
| | Karyotype | 1 | 2014 | 19 | 0.030 |
Why?
| | Capsid | 1 | 2014 | 2 | 0.030 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2014 | 7 | 0.030 |
Why?
| | HIV-1 | 1 | 2014 | 59 | 0.030 |
Why?
| | Homozygote | 1 | 2013 | 59 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 31 | 0.030 |
Why?
| | Genetic Vectors | 1 | 2014 | 128 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1046 | 0.030 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2013 | 4 | 0.030 |
Why?
| | Acrylamides | 1 | 2013 | 8 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2013 | 29 | 0.030 |
Why?
| | Dependovirus | 1 | 2014 | 103 | 0.030 |
Why?
| | Niacinamide | 1 | 2013 | 23 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2013 | 77 | 0.030 |
Why?
| | NAD | 1 | 2013 | 45 | 0.030 |
Why?
| | Amides | 1 | 2013 | 37 | 0.030 |
Why?
| | Nitriles | 1 | 2013 | 53 | 0.030 |
Why?
| | Sirtuin 1 | 1 | 2013 | 29 | 0.030 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 32 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 108 | 0.030 |
Why?
| | Transplantation Chimera | 2 | 2003 | 16 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 213 | 0.020 |
Why?
| | Piperidines | 1 | 2013 | 97 | 0.020 |
Why?
| | Infant | 1 | 2020 | 3733 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2011 | 20 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 373 | 0.020 |
Why?
| | Induction Chemotherapy | 1 | 2012 | 64 | 0.020 |
Why?
| | Chemokine CXCL10 | 1 | 2011 | 20 | 0.020 |
Why?
| | HIV Infections | 1 | 2016 | 389 | 0.020 |
Why?
| | Antibodies, Neutralizing | 1 | 2011 | 78 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 727 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2011 | 50 | 0.020 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2010 | 25 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2010 | 47 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2010 | 48 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 372 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2010 | 71 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2010 | 67 | 0.020 |
Why?
| | Argonaute Proteins | 1 | 2010 | 12 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 128 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2010 | 76 | 0.020 |
Why?
| | Polyploidy | 1 | 2009 | 9 | 0.020 |
Why?
| | Bone Marrow Examination | 1 | 2009 | 11 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2009 | 71 | 0.020 |
Why?
| | Ploidies | 1 | 2008 | 10 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 243 | 0.020 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2008 | 38 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 90 | 0.020 |
Why?
| | Serum Albumin | 1 | 2008 | 58 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 220 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 595 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 174 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2008 | 483 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2007 | 53 | 0.020 |
Why?
| | Multigene Family | 1 | 2006 | 48 | 0.020 |
Why?
| | Cyclin D | 1 | 2006 | 18 | 0.020 |
Why?
| | Syndecans | 1 | 2006 | 37 | 0.020 |
Why?
| | Cyclins | 1 | 2006 | 38 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 45 | 0.020 |
Why?
| | Proteoglycans | 1 | 2006 | 87 | 0.020 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2007 | 203 | 0.020 |
Why?
| | Brain | 1 | 2013 | 1323 | 0.020 |
Why?
| | Survivors | 1 | 2006 | 120 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 2680 | 0.010 |
Why?
| | Lymphocyte Transfusion | 1 | 2003 | 10 | 0.010 |
Why?
| | Probability | 1 | 2003 | 172 | 0.010 |
Why?
| | Administration, Oral | 1 | 2003 | 451 | 0.010 |
Why?
| | Tissue Donors | 1 | 2003 | 126 | 0.010 |
Why?
|
|
Van Rhee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|